Drugs / OM-89
OM-89
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT06345014 | Dec 2023 → Dec 2025 | chronic pain syndrome, chronic prostatitis | AJU Pharm Co., Ltd. | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT06588010 Comparator | Dec 2024 → Dec 2029 expected | cauda equina syndrome with neurogenic bladder | Centre Hospitalier Universitaire Dijon | Recruiting | No outcome recorded |
| Phase 3 | NCT00521924 Comparator | Jun 2007 → Apr 2008 | rheumatoid arthritis | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-09-28 | OM Pharma SA | Results New research provides deeper insights into Uro-Vaxom® (OM-89) ompharma.com ↗
Published in PLOS Pathogens, the study found that OM-89 may help strengthen the bladder's natural defenses against bacteria that can persist after treatment and contribute to recurrent UTIs. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-10-09 | OM Pharma SA | Lotus Pharmaceutical completes acquisition of Uro-Vaxom® marketing authorisation in South Korea ompharma.com ↗ |
| 2026-09-28 | OM Pharma SA | New research provides deeper insights into Uro-Vaxom® (OM-89) ompharma.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OM-89 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06588010 ↗ |
| Known as | Uro-Vaxom | “OM-89 [Uro-Vaxom® Capsule]” NCT06588010 ↗ |
| Known as | Uro-Vaxom Capsule | “OM-89 [Uro-Vaxom® Capsule]” NCT06345014 ↗ |
| Modality | Other / unclassified | “6 mg as a freeze-dried bacterial lysate” NCT06345014 ↗ |
| Route | Oral | “Oral administration of the investigational product (OM-89 [Uro-Vaxom® Capsule] or the placebo) once a day” NCT06345014 ↗ |